GeoffroyPineau-Valencienne

Partner

Paris + 33.1.56.59.39.39

Geoffroy Pineau-Valencienne practices in the area of corporate law with particular focus on venture capital, private equity, M&A, and capital markets. He represents a large number of listed and unlisted high-growth companies at every stage of development, as well as their managers and investors, particularly in the life sciences and technology industries.

In addition, he has significant experience drafting and negotiating commercial agreements and representing industrial groups and emerging companies in connection with R&D licensing and distribution agreements.

Geoffroy's recent experience includes representation of technology and life sciences companies such as Alizé Pharma, Amoéba, Cellectis, Cellnovo, Criteo, Diaxonhit, Genticel, HRA Pharma, Inotrem, Mauna Kea Technologies, Otonnale, Talend, and Trace One. These transactions include the initial public offerings of Amoéba, Genticel, and Enertime on the main or Alternext market of Euronext Paris and of American Depositary Shares (ADS) of Talend on the NASDAQ Global Market, as well as follow-on offerings of Cellectis and Talend on NASDAQ. He also has worked on French and international M&A transactions involving the reverse sale of Genticel to Genkyotex and sale by Alizé Pharma Group of two subsidiaries respectively to Jazz Pharmaceuticals and Millendo Therapeutics.

Geoffroy has represented investors such as Andera Partners, Balderton Capital, BioMed Partners, Bpifrance, CEA Investissement, CITA Investissement, Entrepreneur Venture Gestion, HI Inov, Idinvest Partners, Riverside, Serena Capital, Seventure Partners, Ventech, Wellington Partners, Western Digital, and Xerys Gestion. These representations include Wellington Partners and others in connection with their co-investment in UroMems and TriCares and Idinvest Partners in connection with its investment in Lendix.

Experience

  • Inotrem raises €39 million in Series B financing roundJones Day advised Inotrem S.A., a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €39 million (US$43 million) Series B round of financing led by Morningside Ventures and joined by Invus as well as historical investors including Andera Partners, Sofinnova Partners, and BiomedInvest.
  • Alizé Pharma 3 raises €67 million in financing roundJones Day represented Alizé Pharma 3 SAS, a French company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its €67 million (US$75 million) round of financing led by LSP, and included a syndicate of international investors.
  • Elaia Partners participates in €3.6 million Series A investment in PILIJones Day represented Elaia Partners in connection with its Series A investment in PILI, a French biotech company.
  • Havenrock participates in €4.4 million financing round of SESAMmJones Day assisted Havenrock SAS in connection with the €4.4 million (US$4.9 million) round of financing of a SESAMm, a French leader in Big Data and Artificial Intelligence solutions applied to asset management.
  • Cellectis completes $164 million follow-on public offering of American Depositary Shares on NASDAQJones Day represented Cellectis S.A., a French clinical-stage biopharmaceutical developer of innovative cancer treatments using gene editing technologies, in connection with a $164 million public offering of American Depositary Shares on NASDAQ, underwritten by Goldman Sachs & Co. LLC, Citigroup, and Barclays.
  • Idinvest Partners participates in €32 million Series B financing round of LendixJones Day advised Idinvest Partners SA in connection with its participation in a €32 million (US$37 million) Series B financing round of Lendix, a French fintech company that develops an online platform for business loans.
  • Seventure and Entrepreneur Venture Gestion invest €6 million in IzicapJones Day advised Seventure Partners and Entrepreneur Venture Gestion in connection with the €6 million (US$6.9 million) Series A round of financing of Izicap, a provider of customer relationship marketing tools through consumers bank cards and existing payment terminals.
  • Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScienceJones Day advised Fonds InnoBio, managed by Bpifrance, in connection with the reverse merger of Millendo Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, with OvaScience, Inc. in an all-stock transaction, and concurrent equity financing.
  • Athyrium Capital Management partially issues second tranche of bond issueJones Day advised Athyrium Capital Management, LP in connection with the partial issuance of the second tranche of its bond issue.
  • Alizé Pharma SAS acquired by Millendo Therapeutics, Inc.Jones Day advised Alizé Pharma SAS, a French clinical-stage biotech private company, in connection with its sale in a stock-for-stock transaction to Millendo Therapeutics, Inc., a U.S. clinical-stage biotech private company focused on developing novel treatments for endocrine diseases.
  • Wellington Partners, Andera Partners, and BioMed Partners invest €22 million in TRiCaresJones Day represented Wellington Partners, Andera Partners, and BioMed Partners in connection with the €22 million (US$25.4 million) Series B financing round of TRiCares SAS, a French medtech company pioneer in the field of minimally invasive treatment of tricuspid regurgitation.
  • Talend completes $188.4 million secondary offering of American Depositary Shares on NASDAQ by Selling ShareholdersJones Day represented Talend SA, a French global leader in cloud and big data integration software, in connection with the $188.4 million secondary public offering of American Depositary (each representing one of its ordinary shares) on NASDAQ, by investment funds affiliated with Silver Lake Sumeru and investment funds affiliated with Balderton Capital.
  • Reverse sale of Genticel to GenKyoTex SA to become GenkyotexJones Day advised Genticel SA in connection with its reverse sale to the shareholders of GenKyoTex who received approximately 80 percent of the share capital of Genticel in remuneration of their contribution of GenKyoTex shares to Genticel.
  • Talend completes follow-on public offering on NASDAQ by certain of its main shareholdersJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with the follow-on public offering of American Depositary Shares (ADSs) on NASDAQ by certain of its main shareholders.
  • Talend completes IPO of American Depositary Shares on NASDAQJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with its issuance of $94.5 million of American Depositary Shares in an initial public offering on NASDAQ.
  • New Alpha invests in WiztopicJones Day represented New Alpha Asset Management in connection with its investment in Wiztopic SAS, a publisher of an SaaS solution dedicated to corporate and financial communication executives.
  • Western Digital invests in UPMEMJones Day represented Western Digital, a leading provider of storage technologies and solutions that enable people to create, leverage, experience, and preserve data, in connection with its purchase of Series A Preferred Stock in a private placement by UPMEM, a fabless semiconductor company developing next generation hardware solutions for data intensive applications in the datacenter.
  • Permira Debt Managers provides unitranche financing for acquisition of I@D groupJones Day represented Permira Debt Managers Limited in connection with its unitranche financing for the acquisition of the I@D group, a services platform dedicated to the first network of independent real estate agents in France.
  • Hi Inov invests InterCloudJones Day represented Hi Inov in connection with its investment in InterCloud, a France-based provider of enterprise cloud delivery solutions.
  • Wellington Partners, Bpifrance, CITA Investissement, CEA Investissement, and b-to-v Partners invest in UroMemsJones Day advised Wellington Partners, Bpifrance, CITA Investissement, CEA Investissement, and b-to-v Partners AG in connection with a €12 million ($12.7 million) private placement in UroMems, an innovative medtech company developing an active medical implantable device for treatment of urinary incontinence.
  • Enertime completes IPO on Alternext market of Euronext in ParisJones Day advised Enertime SAS, an innovating Energy solutions developer, along with Portzamparc Société de Bourse, as listing sponsor, in connection with the proposed initial public offering of Enertime on the Alternext market of Euronext in Paris.
  • Apax and Europe Snacks obtain financing for acquisition of Kolak Snack FoodsJones Day represented Apax Partners Midmarket SAS and Europe Snacks in connection with the financing of the acquisition by Europe Snacks of Kolak Snack Foods and the refinancing of its debt.
  • Criteo acquires Monsieur DriveJones Day advised Criteo S.A., a French technology company listed on the NASDAQ specializing in performance display advertising, in connection with its acquisition of Monsieur Drive, a French company which operates and develops digital advertising solutions for consumer brands.
  • Amoéba completes €14.7 million private placement of new sharesJones Day represented Amoéba SAS, a developer of sustainable organic biocide capable of mitigating bacterial risk in water systems, in connection with the €14.7 million (US$16.5 million) private placement of new shares to European and American investors.
  • Amoéba completes €13.2 million IPO on regulated market of Euronext in ParisJones Day advised Amoéba SA, a developer of sustainable organic biocide capable of mitigating bacterial risk in water systems, along with underwriters Bryan, Garnier & Co. and Portzamparc Société de Bourse, in connection with the €13.2 million (US$14.7 million) initial public offering of New Shares on the regulated market of Euronext in Paris.
  • Genticel completes IPO on regulated markets of Euronext in Paris and BrusselsJones Day advised Genticel, S.A., a developer of therapeutic vaccines against HPV infection with high-risk types, in connection with its €34.5 million (US$47.8 million) initial public offering of Ordinary Shares on the regulated markets of Euronext in Paris and in Brussels.
  • BPI France invests in SarenzaJones Day represented BPI France in connection with a €74 million (US$98.9 million) investment led by BPI France and HLD in Sarenza, a French e-Commerce company specializing in the online sale of shoes and accessories.
  • Seventure invests in MinuteBuzzJones Day advised Seventure Partners in connection with its purchase of Series A Preferred Stock in a private placement by MinuteBuzz, a social media entertainment website.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.